The collaboration between BMS and BioNTech, valued up to $11B, aims to expedite BNT327’s market launch and mitigate risks in various settings. This partnership provides BNTX with non-dilutive capital, fortifying its oncology pipeline. Despite modest overall survival hazard ratios compared to progression-free survival, this deal affirms the asset’s value and enhances BNTX’s financial standing for long-term growth. Analysts foresee a shift in focus from COVID towards BNTX’s pipeline advancements post this collaboration.
Read more from genengnews.com
